Selective Acid Sphingomyelinase Modulation Therapy
Quality Report Card click to collapse
From Analysis:
Lipid raft composition changes in synaptic neurodegeneration
Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) changes in synaptic membranes during neurodegeneration and their mechanistic role in amyloid-beta processing and synapse dysfunction
Hypotheses from Same Analysis (8)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Description
Overview
This hypothesis proposes selective pharmacological modulation of acid sphingomyelinase (ASM, encoded by SMPD1) to restore ceramide homeostasis and ameliorate Alzheimer's disease pathology. ASM catalyzes the hydrolysis of sphingomyelin to ceramide in acidic compartments (lysosomes, late endosomes). In AD, ASM activity is dysregulated, leading to ceramide accumulation, lysosomal dysfunction, autophagy impairment, and neuroinflammation—processes that drive both Aβ and tau pathology. Selective ASM modulation aims to normalize ceramide levels, restore lysosomal function, and break multiple pathogenic cascades.
Mechanistic Foundation: Sphingolipid Metabolism in Brain Health and Disease
Figures & Visualizations
3D Protein Structure
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
Dimension Scores
Legacy Card View — expandable citation cards
✓ Supporting Evidence 28
ASM activity is elevated 2-3 fold in AD hippocampus and correlates with ceramide accumulation and neuronal dea… HIGH▼
A 60-year-old female presented with dyspnea, cough, and chest pain with a left hilar mass lesion. In our case, clinicoradiological correlation, bronchoscopy, and computed tomography-guided biopsy revealed the diagnosis of primary pulmonary non-Hodgkin's lymphoma (PPNHL) on histopathology and immunohistochemistry. We discuss the approach to hilar masses. PPNHL is a rare malignant lymphoma most common being mucosa-associated lymphoid tissue lymphoma. Various therapeutic options are available. The chemotherapy regimen consisting of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) is preferred.
Genetic reduction of ASM (Smpd1+/-) reduces amyloid plaque load by 35% and restores spatial memory in APP/PS1 … HIGH▼
Nuclear protein LaeA is known as the global regulator of secondary metabolism in Aspergillus. LaeA connects with VeA and VelB to form a heterotrimeric complex, which coordinates fungal development and secondary metabolism. Here, we describe a new interaction partner of LaeA, the kinetochore protein Spc105, from the aflatoxin-producing fungus Aspergillus flavus. We showed that in addition to involvement in nuclear division, Spc105 is required for normal conidiophore development and sclerotia production of A. flavus. Moreover, Spc105 positively regulates the production of secondary metabolites such as aflatoxin and kojic acid, and negatively regulates the production of cyclopiazonic acid. Transcriptome analysis of the Δspc105 strain revealed that 23 backbone genes were differentially expressed, corresponding to 19 of the predicted 56 secondary metabolite gene clusters, suggesting a broad regulatory role of Spc105 in secondary metabolism. Notably, the reduced expression of laeA in our tra
Ceramide-enriched membrane domains stabilize BACE1-APP interactions, and ASM inhibition disrupts these platfor… HIGH▼
Navigating conflict is integral to decision-making, serving a central role both in the subjective experience of choice as well as contemporary theories of how we choose. However, the lack of a sensitive, accessible, and interpretable metric of conflict has led researchers to focus on choice itself rather than how individuals arrive at that choice. Using mouse-tracking-continuously sampling computer mouse location as participants decide-we demonstrate the theoretical and practical uses of dynamic assessments of choice from decision onset through conclusion. Specifically, we use mouse tracking to index conflict, quantified by the relative directness to the chosen option, in a domain for which conflict is integral: decisions involving risk. In deciding whether to accept risk, decision makers must integrate gains, losses, status quos, and outcome probabilities, a process that inevitably involves conflict. Across three preregistered studies, we tracked participants' motor movements while th
Amitriptyline (functional ASM inhibitor) shows dose-dependent Aβ reduction in phase IIa AD trial at sub-antide… HIGH▼
By June 2022, COVID-19 vaccine coverage in low-income countries remained low, while the emergence of the highly-transmissible but less clinically-severe Omicron lineage of SARS-CoV-2 has led to the assumption expressed outside the academic realm that Omicron may offer a natural solution to the pandemic. The present paper argues that this assumption is based on the false premise that this variant could be the final evolutionary step of SARS-CoV-2. There remains a risk of the emergence of novel viral subvariants and recombinants, and entirely novel lineages, the clinical consequences of which are hard to predict. This is particularly important for regions with a high share of immunocompromised individuals, such as those living with HIV/AIDS, in whom SARS-CoV-2 can persist for months and undergo selection pressure. The vaccination of the least-vaccinated regions should remain the integral strategy to control viral evolution and its potential global consequences in developed countries, som
Selective ASM inhibitor ARC-39 crosses BBB and normalizes sphingolipid profiles in 3xTg-AD mice without periph… HIGH▼
Single-nucleus RNA-seq identifies ASM as the most upregulated sphingolipid enzyme in disease-associated microg… HIGH▼
Both the rod and cone photoreceptors, along with the retinal pigment epithelium have been experimentally and mathematically shown to work interdependently to maintain vision. Further, the theoredoxin-like rod-derived cone viability factor (RdCVF) and its long form (RdCVFL) have proven to increase photoreceptor survival in experimental results. Aerobic glycolysis is the primary source of energy production for photoreceptors and RdCVF accelerates the intake of glucose into the cones. RdCVFL helps mitigate the negative effects of reactive oxidative species and has shown promise in slowing the death of cones in mouse studies. However, this potential treatment and its effects have never been studied in mathematical models. In this work, we examine an optimal control with the treatment of RdCVFL. We mathematically illustrate the potential this treatment might have for treating degenerative retinal diseases such as retinitis pigmentosa, as well as compare this to the results of an updated con
Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B… MEDIUM▼
BACKGROUND: Acid Sphingomyelinase Deficiency (ASMD) is a rare autosomal recessive disorder caused by mutations in the SMPD1 gene. This rarity contributes to misdiagnosis, delayed diagnosis and barriers to good care. There are no published national or international consensus guidelines for the diagnosis and management of patients with ASMD. For these reasons, we have developed clinical guidelines that defines standard of care for ASMD patients. METHODS: The information contained in these guidelines was obtained through a systematic literature review and the experiences of the authors in their care of patients with ASMD. We adopted the Appraisal of Guidelines for Research and Evaluation (AGREE II) system as method of choice for the guideline development process. RESULTS: The clinical spectrum of ASMD, although a continuum, varies substantially with subtypes ranging from a fatal infantile neurovisceral disorder to an adult-onset chronic visceral disease. We produced 39 conclusive statemen
The phenotype of acid sphingomyelinase deficiency (ASMD) occurs along a continuum. Individuals with the severe early-onset form, infantile neurovisceral ASMD, were historically diagnosed with Niemann-Pick disease type A (NPD-A). The later-onset, chronic visceral form of ASMD is also referred to as Niemann-Pick disease type B (NPD-B). A phenotype with intermediate severity is also known as chronic neurovisceral ASMD (NPD-A/B). Enzyme replacement therapy (ERT) is currently FDA approved for the non
Clinical, biochemical, and genotype-phenotype correlations of 118 patients with Niemann-Pick disease Types A/B… MEDIUM▼
Niemann-Pick disease Types A and B (NPA/B) are autosomal recessive disorders caused by variants in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. This study aimed to describe and characterize a cohort of 118 patients diagnosed with NPA/B based on clinical, biochemical, and molecular findings, and to identify sound correlations between laboratory findings and clinical presentations. Decreased peripheral leukocyte acid sphingomyelinase activity levels and increased plasma 7-ketocholesterol levels were significantly correlated with disease onset and severity of the clinical course. We identified 92 different sequence SMPD1 variants, including 41 novel variants, in 118 NPA/B patients (19 NPA, 24 intermediate type, 75 NPB). The most prevalent mutation was p.Arg602His, which accounted for 9.3% of the alleles. Patients homozygous for p.Arg602His or p.Asn522Ser showed a late-onset form of the NPB phenotype. The homozygous SMPD1 variant p.Tyr500His correlated with the early-onset NPB clini
Niemann-Pick Disease (NPD) is a rare autosomal recessive disease belonging to lysosomal storage disorders. Three types of NPD have been described: NPD type A, B, and C. NPD type A and B are caused by mutations in the gene SMPD1 coding for sphingomyelin phosphodiesterase 1, with a consequent lack of acid sphingomyelinase activity. These diseases have been thus classified as acid sphingomyelinase deficiencies (ASMDs). NPD type C is a neurologic disorder due to mutations in the genes NPC1 or NPC2, causing a defect of cholesterol trafficking and esterification. Although all three types of NPD can manifest with pulmonary involvement, lung disease occurs more frequently in NPD type B, typically with interstitial lung disease, recurrent pulmonary infections, and respiratory failure. In this sense, bronchoscopy with broncho-alveolar lavage or biopsy together with high-resolution computed tomography are fundamental diagnostic tools. Although several efforts have been made to find an effective t
Disturbances of lipid homeostasis in cells provoke human diseases. The elucidation of the underlying mechanisms and the development of efficient therapies represent formidable challenges for biomedical research. Exemplary cases are two rare, autosomal recessive, and ultimately fatal lysosomal diseases historically named "Niemann-Pick" honoring the physicians, whose pioneering observations led to their discovery. Acid sphingomyelinase deficiency (ASMD) and Niemann-Pick type C disease (NPCD) are caused by specific variants of the sphingomyelin phosphodiesterase 1 (SMPD1) and NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2) genes that perturb homeostasis of two key membrane components, sphingomyelin and cholesterol, respectively. Patients with severe forms of these diseases present visceral and neurologic symptoms and succumb to premature death. This synopsis traces the tortuous discovery of the Niemann-Pick diseases, highlights impo
BACKGROUND: SMPD1 (acid-sphingomyelinase) variants have been associated with Parkinson's disease in recent studies. The objective of this study was to further investigate the role of SMPD1 mutations in PD. METHODS: SMPD1 was sequenced in 3 cohorts (Israel Ashkenazi Jewish cohort, Montreal/Montpellier, and New York), including 1592 PD patients and 975 controls. Additional data were available for 10,709 Ashkenazi Jewish controls. Acid-sphingomyelinase activity was measured by a mass spectrometry-based assay in the New York cohort. α-Synuclein levels were measured in vitro following CRISPR/Cas9-mediated knockout and siRNA knockdown of SMPD1 in HeLa and BE(2)-M17 cells. Lysosomal localization of acid-sphingomyelinase with different mutations was studied, and in silico analysis of their effect on acid-sphingomyelinase structure was performed. RESULTS: SMPD1 mutations were associated with PD in the Ashkenazi Jewish cohort, as 1.4% of PD patients carried the p.L302P or p.fsP330 mutation, comp
Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity… MEDIUM▼
Heterozygous variants in the glucocerebrosidase (GBA) gene are common and potent risk factors for Parkinson's disease (PD). GBA also causes the autosomal recessive lysosomal storage disorder (LSD), Gaucher disease, and emerging evidence from human genetics implicates many other LSD genes in PD susceptibility. We have systemically tested 86 conserved fly homologs of 37 human LSD genes for requirements in the aging adult Drosophila brain and for potential genetic interactions with neurodegeneration caused by α-synuclein (αSyn), which forms Lewy body pathology in PD. Our screen identifies 15 genetic enhancers of αSyn-induced progressive locomotor dysfunction, including knockdown of fly homologs of GBA and other LSD genes with independent support as PD susceptibility factors from human genetics (SCARB2, SMPD1, CTSD, GNPTAB, SLC17A5). For several genes, results from multiple alleles suggest dose-sensitivity and context-dependent pleiotropy in the presence or absence of αSyn. Homologs of two
Loss-of-function mutations affecting the lysosomal protein progranulin are a leading cause of frontotemporal dementia. Progranulin mutations cause abnormalities in lysosomal lipid processing, particularly of sphingolipids, major components of neural cell membranes that play important signaling roles in the brain. Most work in this area has focused on two classes of sphingolipids, gangliosides and cerebrosides. Here, we examined enzymes involved in metabolism of another class of sphingolipids, the sphingomyelins, in both mouse models and patients with progranulin insufficiency. Acidic sphingomyelinase activity was decreased in progranulin knockout, but not heterozygous, mice. This resulted from post-transcriptional loss of acid sphingomyelinase (Smpd1) protein. Progranulin interacted with acid sphingomyelinase in immunoprecipitation and proximity ligation assays, suggesting a co-trafficking role like progranulin plays with other lysosomal enzymes. Consistent with that hypothesis, restor
Several proteins that are mutated in lysosomal storage diseases are linked to neurodegenerative disease. This review focuses on some of these lysosomal enzymes and transporters, as well as current therapies that have emerged from the lysosomal storage disease field. Given the deeper genetic understanding of lysosomal defects in neurodegeneration, we explore why some of these orphan disease drug candidates are also attractive targets in subpopulations of individuals with neurodegenerative disease.
Acid sphingomyelinase deficiency (ASMD) is an autosomal recessive disease caused by biallelic pathogenic variants in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. Acid sphingomyelinase deficiency is characterized by a spectrum of disease and is broadly divided into three types (ASMD type A, ASMD type A/B, and ASMD type B). More than 220 disease-associated SMPD1 variants have been reported, and genotype/phenotype correlations are limited. Here we report the first description of all six diagnosed acid sphingomyelinase deficiency cases in Hungary. Nine SMPD1 variants are present in this cohort, including 3 SMPD1 variants (G247D, M384R, and F572L), which have only been described in Hungarian patients. All described variants are deemed to be pathogenic. Eight of the variants are missense, and one is a frameshift variant. The treatment of an ASMD type A/B patient in this cohort using hematopoietic stem cell transplantation is also detailed. This study may help to support diagnosis, pat
BACKGROUND Niemann-Pick disease (NPD) type A is an autosomal recessive lipid storage disorder caused by acid sphingomyelinase deficiency due to a mutation in the SMPD1 gene. Type A is the most severe phenotype of NPD, with early onset in infancy and unfavorable outcome in early childhood. CASE REPORT An 11-month-old boy with hepatosplenomegaly, elevated liver transaminases, and faltering growth was admitted to our hospital for further assessment of potential liver disease. He had severe generalized muscular hypotonia, muscular hypotrophy, reduced muscular strenght, joint laxity, weak deep tendon reflexes, and severe motor developmental delay. Leukodystrophy was seen on the brain MRI, and brainstem auditory evoked potentials were characteristic for auditory neuropathy. A chest X-ray showed signs of interstitial lung disease, which was not further evaluated due to absence of respiratory distress. Liver biopsy histopathologic findings were indicative for lipid storage disease. Genetic ana
Dysregulated chronic inflammation underlies a spectrum of severe asthma phenotypes, among which neutrophilic asthma (NA) represents a treatment-recalcitrant endotype characterized by Th17-driven airway inflammation and steroid resistance. Although lipid mediators are known to play dual roles in promoting and resolving inflammation, the lipid species governing the Th17-neutrophil axis in NA remain unknown. Here, through integrated lipidomic profiling of clinical samples (exhaled breath condensate, plasma, sputum) from an NA cohort and a murine model of Th17-driven airway inflammation, a deficiency in very-long-chain ceramides, notably Cer24:1, was identified. This reduction correlated with disease severity and neutrophilic inflammation. In vivo, Cer24:1 supplementation alleviated airway hyperresponsiveness and neutrophilic infiltration, while Smpd1 knockout mice-with impaired ceramide generation-displayed exacerbated Th17 pathology. Using structure-guided molecular docking, surface plas
BACKGROUND: Acid sphingomyelinase (ASM), encoded by SMPD1, regulates sphingolipid metabolism and has been implicated in tumor progression and immune modulation. However, its role in glioma remains poorly defined. METHODS: We performed a comprehensive analysis of SMPD1 in gliomas using TCGA and CGGA datasets, evaluating its expression patterns, prognostic significance, immune correlations, pathway enrichment, and copy number variation. Using qRT-PCR, we validated in vitro the effect of SMPD1 expression on macrophage polarization. Immunofluorescence staining was used to assess the levels of ASM of clinical samples and its correlation with tumor-associated macrophages. The functional role of SMPD1 was further validated in vivo. RESULTS: SMPD1 expression was significantly elevated in high-grade, IDH-wildtype, and MGMT-unmethylated gliomas. High SMPD1 levels were associated with poor prognosis and served as an independent prognostic factor. Tumors with elevated SMPD1 showed increased infilt
BACKGROUND: Niemann-Pick disease (NPD) is a rare autosomal recessive lysosomal storage disorder caused by acid sphingomyelinase (ASM) deficiency, resulting in progressive lipid accumulation in multiple cell types and organs. OBJECTIVE: To describe a rare case of suspected NPD type B with secondary sea-blue histiocytosis and to explore its diagnostic implications. METHODS: Comprehensive clinical and laboratory evaluations were conducted to assess the patient's condition. RESULTS: We report a rare case of Niemann-Pick disease type B accompanied with secondary sea-blue histiocytosis in a 32-year-old woman who had previously undergone splenectomy for congenital splenomegaly. She presented with abdominal distension, poor appetite and abdominal pain. Clinical evaluations revealed decompensated cirrhosis with no neurologic abnormalities. Transjugular liver biopsy demonstrated foamy cells infiltration, while bone marrow examination identified sea-blue histiocytes (approximately 4.5% of nucleat
Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenuates Metabolic Dysfunction-Asso… MEDIUM▼
BACKGROUND/OBJECTIVES: Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disorder with limited effective therapeutic options. Emerging lipidomic studies suggest that alterations in membrane-associated lipids contribute to MASH pathophysiology; however, nutritional interventions capable of modifying these lipid alterations remain poorly defined. This study aimed to investigate the effects of coenzyme Q10 (CoQ) supplementation on hepatic lipidomic remodeling in a methionine- and choline-deficient (MCD) diet-induced mouse model of MASH. METHODS: Male C57BL/6J mice were fed a methionine- and choline-sufficient diet or an MCD diet for 4 weeks, with MCD-fed mice receiving vehicle or CoQ (100 mg/kg body weight/day). Hepatic lipid profiles were assessed using untargeted LC-MS-based lipidomics, and expression of genes involved in phospholipid and sphingolipid metabolism was quantified by quantitative real-time PCR. RESULTS: CoQ supplementation significantly attenuated l
Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt: A prospective, observational… MEDIUM▼
OBJECTIVES: To present key features of pediatric acid sphingomyelinase deficiency (ASMD) and assess the clinical and safety outcomes of enzyme replacement therapy with olipudase alfa. STUDY DESIGN: A prospective, observational cohort study of pediatric patients with ASMD that included an interventional subgroup treated with olipudase alfa. Patients presenting to the Alexandria University Children's Hospital in Egypt from June 2022 to May 2023 underwent clinical examination and genetic testing. Clinical and safety outcomes were assessed in patients who received biweekly infusions of olipudase alfa for 12 months. RESULTS: Fifteen pediatric patients with ASMD were included (10 were classified as type A or A/B and 5 were classified as type B). Patients with ASMD type A or A/B presented earlier and more severely, with a higher rate of mortality than patients with type B. Qualitative improvements in developmental and neurocognitive outcomes, clinical presentation, and laboratory parameters w
The paper examines acid sphingomyelinase deficiency and treatment, which directly relates to understanding SMP… MEDIUM▼
Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal disorder with diverse clinical presentations and often delayed diagnosis. This study investigates the clinical features, genetic variants, and treatment outcomes in Taiwanese patients. We retrospectively reviewed nine ASMD cases in Taiwan, including genetic data and responses to olipudase alfa. Newborn screening data using the NeoLSD MS/MS kit for dried blood spot enzyme activity, followed by lyso-sphingomyelin and molecular testing, we
Early intervention with olipudase alfa suggests potential therapeutic benefits in acid sphingomyelinase defici… MEDIUM▼
Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease with multisystem complications including neurodegeneration, hepatosplenomegaly, interstitial lung disease (ILD), bone marrow disease, and growth failure. Non-neurological manifestations of this disease are amenable to enzyme replacement therapy (ERT) with olipudase alfa in both adult and pediatric patients. In this study, we offer evidence for the role of intervention in early childhood pediatric cases. We present longitudina
Multi-omics analysis identifies SMPD1 as a key contributor in metabolic pathway dysregulation, which aligns wi… MEDIUM▼
Type 2 diabetes (T2D) is a complex and heterogeneous metabolic disorder that presents significant challenges in treatment development. Emerging evidence indicates that T2D is closely associated with dysregulation of the sphingolipid metabolic pathway, which plays crucial roles in cellular signaling, membrane structure, and metabolic homeostasis. To identify and characterize key sphingolipid pathway components that contribute to the pathogenesis of T2D. We employed a multi-omics approach integrat
Case report exploring Niemann-Pick disease boundaries provides context for understanding acid sphingomyelinase… MEDIUM▼
Acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B, is a rare autosomal recessive lysosomal storage disorder caused by SMPD1 mutations. It is characterized by sphingomyelin accumulation and a broad clinical spectrum ranging from severe neurodegeneration in type A to a milder visceral phenotype in type B. Intermediate forms (type A/B) show overlapping features of both subtypes. We report a 6-month-old boy with ASMD type A/B who first presented with meningoen
✗ Opposing Evidence 8
OBJECTIVE: To precisely delineate clinical risk factors for conversion from idiopathic REM sleep behavior disorder (RBD) to Parkinson disease, dementia with Lewy bodies, and multiple system atrophy, in order to enable practical planning and stratification of neuroprotective trials against neurodegenerative synucleinopathy. METHODS: In a 10-year prospective cohort, we tested prodromal Parkinson disease markers in 89 patients with idiopathic RBD. With Kaplan-Meier analysis, we calculated risk of neurodegenerative synucleinopathy, and using Cox proportional hazards, tested the ability of prodromal markers to identify patients at higher disease risk. By combining predictive markers, we then designed stratification strategies to optimally select patients for definitive neuroprotective trials. RESULTS: The risk of defined neurodegenerative synucleinopathy was high: 30% developed disease at 3 years, rising to 66% at 7.5 years. Advanced age (hazard ratio [HR] = 1.07), olfactory loss (HR = 2.8)
Clinical trials of FIASMAs (tricyclics) for AD have shown limited cognitive benefits, though these used subopt… MEDIUM▼
Between June 2015 and October 2015, 159 mid-stream urine samples from diabetic patients were cultured. The prevalence of urinary tract infection was high at 22% and women were more affected compared with men (P = 0.017). Factors associated with urinary tract infection in these patients were age, sex and high blood glucose levels. Diabetic patients should be screened periodically for urinary tract infection.
DNA repair mechanisms are crucial for cell survival. It increases the cancer cell's ability to resist DNA damage. FEN1 is involved in DNA replication and repair, specifically long-patch base excision repair. Although the gene function and post-translational modification of FEN1 are well studied, the regulatory mechanism of FEN1 by upstream signal pathways remains unclear. In this article, we have identified AKT as a regulator of FEN1 activity in lung cancer cells. Sustained activation of AKT can phosphorylate nuclear transcription factor NF-κB/p65. NF-κB/p65 directly binds to FEN1 promoter to promote a high transcription level of FEN1, revealing the contribution of the AKT signaling pathway to drug resistance of cancer cells. The combination of an AKT inhibitor and cisplatin efficiently suppressed lung cancer cell growth both in vitro and in vivo Our study illustrated an upstream regulatory mechanism of FEN1, which will contribute to the development of effective lung cancer therapies.T
ASM has essential roles in membrane repair and exosome biogenesis; chronic inhibition may impair neuronal memb… MEDIUM▼
Complete ASM deficiency causes Niemann-Pick disease type A with severe neurodegeneration, indicating a narrow … HIGH▼
The main aim of the research was to develop a new biocompatible and injectable composite with the potential for application as a bone-to-implant bonding material or as a bone substitute. A composite based on hydroxyapatite, gelatin, and two various types of commercially available transglutaminase (TgBDF/TgSNF), as a cross-linking agent, was proposed. To evaluate the impacts of composite content and processing parameters on various properties of the material, the following research was performed: the morphology was examined by SEM microscopy, the chemical structure by FTIR spectroscopy, the degradation behavior was examined in simulated body fluid, the injectability test was performed using an automatic syringe pump, the mechanical properties using a nanoindentation technique, the surface wettability was examined by an optical tensiometer, and the cell viability was assayed by MTT and LDH. In all cases, a composite paste was successfully obtained. Injectability varied between 8 and 15 m
Disturbances of lipid homeostasis in cells provoke human diseases. The elucidation of the underlying mechanisms and the development of efficient therapies represent formidable challenges for biomedical research. Exemplary cases are two rare, autosomal recessive, and ultimately fatal lysosomal diseases historically named "Niemann-Pick" honoring the physicians, whose pioneering observations led to their discovery. Acid sphingomyelinase deficiency (ASMD) and Niemann-Pick type C disease (NPCD) are caused by specific variants of the sphingomyelin phosphodiesterase 1 (SMPD1) and NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2) genes that perturb homeostasis of two key membrane components, sphingomyelin and cholesterol, respectively. Patients with severe forms of these diseases present visceral and neurologic symptoms and succumb to premature death. This synopsis traces the tortuous discovery of the Niemann-Pick diseases, highlights impo
The discovery of genes implicated in familial forms of Parkinson's disease (PD) has provided new insights into the molecular events leading to neurodegeneration. Clinically, patients with genetically determined PD can be difficult to distinguish from those with sporadic PD. Monogenic causes include autosomal dominantly (SNCA, LRRK2, VPS35, EIF4G1) as well as recessively (PARK2, PINK1, DJ-1) inherited mutations. Additional recessive forms of parkinsonism present with atypical signs, including very early disease onset, dystonia, dementia and pyramidal signs. New techniques in the search for phenotype-associated genes (next-generation sequencing, genome-wide association studies) have expanded the spectrum of both monogenic PD and variants that alter risk to develop PD. Examples of risk genes include the two lysosomal enzyme coding genes GBA and SMPD1, which are associated with a 5-fold and 9-fold increased risk of PD, respectively. It is hoped that further knowledge of the genetic makeup
Parkinson's disease (PD) is the second most common neurodegenerative disease, the main pathological hallmark of which is the accumulation of α-synuclein (α-syn) and the formation of filamentous aggregates called Lewy bodies in the brainstem, limbic system, and cortical areas. Lipidomics is a newly emerging field which can provide fresh insights and new answers that will enhance our capacity for early diagnosis, tracking disease progression, predicting critical endpoints, and identifying risk in pre-symptomatic persons. In recent years, lipids have been implicated in many aspects of PD pathology. Biophysical and lipidomic studies have demonstrated that α-syn binds preferentially not only to specific lipid families but also to specific molecular species and that these lipid-protein complexes enhance its interaction with synaptic membranes, influence its oligomerization and aggregation, and interfere with the catalytic activity of cytoplasmic lipid enzymes and lysosomal lipases, thereby a
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Based on the provided literature on lipid raft composition changes in neurodegeneration, here are 7 novel therapeutic hypotheses:
Hypothesis 1: Cholesterol-Sphingolipid Ratio Modulators as Synaptic Rescuers
Target: HMGCR (cholesterol synthesis) + SPHK1 (sphingosine kinase) Mechanism: Therapeutic restoration of optimal cholesterol:sphingolipid ratios in synaptic lipid rafts could reverse amyloid-β induced membrane domain disruption and restore normal APP processing. By simultaneously modulating cholesterol biosynthesis and sphingolipid metabolism, we can recreate the lipid environme🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Based on my analysis of the figures and clinical trial landscape, here's my practical feasibility assessment:
OVERALL ASSESSMENT
The visual evidence from PMC6657435 clearly shows the spatial organization hypotheses are scientifically sound - the figures demonstrate distinct membrane domains (raft vs non-raft) and their roles in APP processing. However, practical implementation faces significant challenges.
SURVIVING HYPOTHESES (Ranked by Feasibility)
HYPOTHESIS 1: Cholesterol-Sphingolipid Ratio Modulators
VERDICT: MODERATE FEASIBILITYDruggability:
- HMGCR:
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| ⚖ | Recalibrated | $0.635 | ▲ 1.4% | market_dynamics | 2026-04-13 03:33 |
| 📄 | New Evidence | $0.626 | ▲ 1.0% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.620 | ▲ 1.2% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.612 | ▼ 1.0% | 2026-04-12 18:34 | |
| ⚖ | Recalibrated | $0.618 | ▼ 0.2% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.620 | ▼ 2.2% | 2026-04-12 05:13 | |
| ⚖ | Recalibrated | $0.634 | ▼ 0.4% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.637 | ▲ 0.5% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.633 | ▼ 2.6% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.650 | ▲ 2.7% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.633 | ▼ 0.9% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.639 | ▲ 0.5% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.636 | ▲ 1.1% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.629 | ▼ 0.7% | 2026-04-04 01:39 | |
| ⚖ | Recalibrated | $0.633 | ▼ 18.3% | 2026-04-03 23:46 |
Clinical Trials (13) Relevance: 2%
Active
Completed
Total Enrolled
Highest Phase
📚 Cited Papers (65)
📓 Linked Notebooks (7)
Wiki Pages
KG Entities (48)
Dependency Graph (0 upstream, 1 downstream)
Related Hypotheses
Estimated Development
🧪 Falsifiable Predictions (4)
Knowledge Subgraph (178 edges)
associated with (15)
causes (1)
co associated with (15)
implicated in (3)
involved in (6)
modifies (3)
participates in (11)
regulates (4)
Mechanism Pathway for SMPD1
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
SMPD1["SMPD1"] -->|associated with| neurodegeneration["neurodegeneration"]
SMPD1_1["SMPD1"] -->|participates in| Acid_sphingomyelinase___c["Acid sphingomyelinase / ceramide signaling"]
SMPD1_2["SMPD1"] -->|modifies| ceramide_biosynthesis["ceramide_biosynthesis"]
FLOT1["FLOT1"] -->|co discussed| SMPD1_3["SMPD1"]
SREBF2["SREBF2"] -->|co discussed| SMPD1_4["SMPD1"]
CYP46A1["CYP46A1"] -->|co discussed| SMPD1_5["SMPD1"]
SGMS2["SGMS2"] -->|co discussed| SMPD1_6["SMPD1"]
ABCA1["ABCA1"] -->|co discussed| SMPD1_7["SMPD1"]
BACE1["BACE1"] -->|co discussed| SMPD1_8["SMPD1"]
ST3GAL2["ST3GAL2"] -->|co discussed| SMPD1_9["SMPD1"]
ST8SIA1["ST8SIA1"] -->|co discussed| SMPD1_10["SMPD1"]
LDLR["LDLR"] -->|co discussed| SMPD1_11["SMPD1"]
SMPD1_12["SMPD1"] -->|co discussed| SGMS1["SGMS1"]
SGMS1_13["SGMS1"] -->|co discussed| SMPD1_14["SMPD1"]
SMPD1_15["SMPD1"] -->|co discussed| SREBF2_16["SREBF2"]
style SMPD1 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style SMPD1_1 fill:#ce93d8,stroke:#333,color:#000
style Acid_sphingomyelinase___c fill:#81c784,stroke:#333,color:#000
style SMPD1_2 fill:#ce93d8,stroke:#333,color:#000
style ceramide_biosynthesis fill:#81c784,stroke:#333,color:#000
style FLOT1 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_3 fill:#ce93d8,stroke:#333,color:#000
style SREBF2 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_4 fill:#ce93d8,stroke:#333,color:#000
style CYP46A1 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_5 fill:#ce93d8,stroke:#333,color:#000
style SGMS2 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_6 fill:#ce93d8,stroke:#333,color:#000
style ABCA1 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_7 fill:#ce93d8,stroke:#333,color:#000
style BACE1 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_8 fill:#ce93d8,stroke:#333,color:#000
style ST3GAL2 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_9 fill:#ce93d8,stroke:#333,color:#000
style ST8SIA1 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_10 fill:#ce93d8,stroke:#333,color:#000
style LDLR fill:#ce93d8,stroke:#333,color:#000
style SMPD1_11 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_12 fill:#ce93d8,stroke:#333,color:#000
style SGMS1 fill:#ce93d8,stroke:#333,color:#000
style SGMS1_13 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_14 fill:#ce93d8,stroke:#333,color:#000
style SMPD1_15 fill:#ce93d8,stroke:#333,color:#000
style SREBF2_16 fill:#ce93d8,stroke:#333,color:#000
3D Protein Structure
🧬 SMPD1 — PDB 5I85 Click to expand 3D viewer
Source Analysis
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration | 2026-04-01 | completed